Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amifostine plus Topotecan in MDS
NCT00003415Phase 2Completed
- Sponsor
- University of Arizona
- Start
- Sep 1998
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of topotecan in myelodysplastic syndrome (MDS), sponsored by University of Arizona. Primary endpoints: Hematologic Response, Cytogenetic Response and 1 more. Started Sep 1998; status: completed.
02
Drugs
topotecan
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00003415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003415.